2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1685

Factors Associated with the 6-Minute Walk Distance in Patients with Systemic Sclerosis
Abstract Number: 75

Factors Associated with TNF Receptor 2 Levels Above the Measurable Range in Rheumatoid Arthritis
Abstract Number: 434

Factors Associated with Treatment Adherence in Rheumatoid Arthritis: A Systematic Literature Review
Abstract Number: 329

Factors Associated with Worsening Serum Vitamin D Deficiencies in Japanese Patients with Rheumatoid Arthritis: Results from the IORRA Cohort Study
Abstract Number: 1653

Factors Influencing on Health-Related Quality of Life in Female Systemic Lupus Erythematosus Patients with Fibromyalgia
Abstract Number: 1439

Factors Influencing the Prescription of Tocilizumab Alone or in Combination with Dmards in Rheumatoid Arthritis Patients in a Real Life Setting. Pooled Analysis of 2 Observational Studies
Abstract Number: 2275

Factors Related to Sustained Discontinuation of Medications for Well-Controlled JIA in the Childhood Arthritis & Rheumatology Research Alliance Registry
Abstract Number: 411

Factors That Drive Treatment Recommendation during Rheumatoid Arthritis Patient´s Follow-up, Differ According to Physician Experience
Abstract Number: 2113

Familial Mediterranean Fever in Chinese Adult Patients
Abstract Number: 565

Fatigue in Primary Sjögren’s Syndrome (pSS) Is Associated with Lower Levels of Proinflammatory Cytokines: A Validation Study
Abstract Number: 1602

Fatigue in Systemic Lupus: The Role of Disease Activity and Its Mediators
Abstract Number: 1388

Fatigue Is Strongly Associated with the Patient Global Assessment and May Affect Disease Severity and Clinical Remission in Patients with Rheumatoid Arthritis: A Cross-Sectional Study from IORRA, a Large Observational Cohort of Japanese Rheumatoid Arthritis Patients
Abstract Number: 1354

Fatigue, Poor Health and Mood Disturbance Persist in Rheumatoid Arthritis and Psoriatic Arthritis Patients Despite Disease Remission: The OPAL Deeper Study
Abstract Number: 1189

Favorable Human Safety, Pharmacokinetics and Pharmacodynamics of the Adamts-5 Inhibitor GLPG1972, a Potential New Treatment in Osteoarthritis
Abstract Number: 2016

Favourable Changes in Power Doppler Scores in the Feet over 1-Year in an Early Rheumatoid Arthritis Cohort: The Role of Rheumatoid Factor and Anti–Citrullinated Protein Antibody

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].